source
- Vaderis raises $152 million Series B to launch Phase 3 trial for rare vascular diseaseVaderis Therapeutics announced it has closed an oversubscribed $152 million Series B round to fund its AKT inhibitor program. The capital will support a newly launched Phase 3 study of the oral dr…
- FDA issues complete response letter rejecting ITM’s neuroendocrine tumor drug over manufacturing concernsThe U.S. Food and Drug Administration sent a complete response letter to ITM Isotopes Technologies, refusing approval of its lead candidate for gastroenteropancreatic neuroendocrine tumors because…